INTRODUCTION
============

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are the leading causes of liver cirrhosis and hepatocellular carcinoma.^[@R1],[@R2]^ In HBV and HCV high endemic areas, such as the Asia-Pacific region, dual infection with HBV and HCV is not uncommon. Approximately 10% of patients are dually infected with both viruses in Taiwan.^[@R3]^ Dually infected patients have been at a much higher risk for the aggravation and progression of liver disease than those with monoinfection.^[@R4],[@R5]^

Current guidelines for the management of HBV/HCV dual infections suggest that which virus is dominant for patients with concurrent HBV/HCV dual infections should be determined and to accordingly treat patients as monoinfections.^[@R6]^ PEGylated interferon (Peg-IFN) and ribavirin (RBV) combination therapy is the currently standard of care for HBV/HCV dually infected patients with active hepatitis C: 48 weeks of Peg-IFN/RBV for HCV genotype 1 (HCV-1)/HBV dually infected patients and 24 weeks of Peg-IFN/RBV for HCV-2/HBV dually infected patients.^[@R7]^ With the strategy of genotype-guided therapy (GGT), the sustained virological response (SVR) rate of HCV was comparable between HCV/HBV dually infected patients and HCV-monoinfected patients (around 75% for HCV-1 and 85% for HCV-2, respectively).^[@R8]^ Additionally, IFN plus RBV therapy also effectively suppressed HBV replication. Long-term follow-up studies in HBV/HCV dually infected patients also revealed a high cumulative hepatitis B surface antigen (HBsAg) seroclearance rate after IFN/RBV therapy.^[@R9],[@R10]^

Response-guided therapy (RGT) based on on-treatment virological responses has achieved comparable efficacy for HCV monoinfected patients when compared to those with standard duration of Peg-IFN/RBV. A similar SVR rate between 24 and 48 weeks Peg-IFN/RBV therapy was observed in HCV-1 monoinfected patients with low baseline viral loads (LVLs) and a rapid virological response (RVR).^[@R11]--[@R14]^ Similarly, 16 weeks of Peg-IFN plus weight-based RBV is recommended for HCV-2/3 patients with an RVR.^[@R14]--[@R18]^ However, whether the concept of RGT with Peg-FIN/RBV can be applied in patients with HBV/HCV dual infections with active hepatitis C has not been studied.

This randomized-controlled study aimed to investigate the efficacy of a tailored regimen of Peg-IFN/RBV based on RGT in the treatment of patients with HBV and active HCV dual infections.

MATERIALS AND METHODS
=====================

Study Population
----------------

This is an open label, randomized-controlled, comparative trial, conducted in a medical center in the Southern Taiwan. Eligible subjects were previously untreated patients or had previously failed interferon monotherapy with chronic HBV/HCV dual infections, aged 18 to 65 years, who were seropositive for HBsAg, HCV antibodies (Anti-HCV) and HCV RNA for \>6 months; were seronegative for hepatitis B e antigen (HBeAg); and serum alanine aminotransferase levels between 1 and 10-fold of the upper limit of normal (ULN). Other eligibility criteria included neutrophil count \>1500 mm^3^, platelet count \>9 × 104 mm^3^, hemoglobin level \>12 g/dL for men and \>11 g/dL for women, no pregnancy or lactation, and the use of a reliable method of contraception.

The exclusion criteria included human immunodeficiency virus infection, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, Wilson disease, α1-antitrypsin deficiency, overt hepatic failure, psychiatric condition, previous liver transplantation, with evidence of hepatocellular carcinoma, decompensated liver disease (Child--Pugh score ≥7); pregnant or breast-feeding women; serum creatinine ≥2 mg/dL; evidence of alcoholism or drug abuse; any other known disease that was not suitable for Peg-IFN therapy.

Study Design
------------

The study design is illustrated in Figure [1](#F1){ref-type="fig"}. Eligible subjects were randomized into 2 groups at treatment initiation. Subjects who were randomized into the GGT group received Peg-IFN and weight-based dose RBV (1000--1200 mg/day) for 48 weeks in subjects dually infected with HCV-1/HBV or Peg-IFN and fixed low dose RBV (800 mg/day) for 24 weeks in subjects dually infected with HCV-2/3/HBV; the patients were then followed for 6 months. For subjects who were randomized into the RGT group, all patients were treated with Peg-IFN and weight-based RBV. For HCV-1/HBV dually infected patients, treatment duration was 24 weeks for patients with a low LVL (LVL, \<400,000 IU/mL, defined based on our previous study^[@R11]^) and RVR (HCV RNA undetectable at treatment week 4); the others were treated with 48-week regimen. For HCV-2/3/HBV dually infected patients, the treatment duration was 16 weeks for patients with RVR; the others were treated with 24 weeks. The randomization was performed by computer software.

![Study design of the open label, randomized-controlled, comparative trial. G-1 = genotype 1, G-2/3 = genotype 2/3, GGT = genotype guided therapy, HVL = high viral load, pretreatment HCV RNA \>400,000 IU/mL, LD RBV = low dose ribavirin, 800 mg/day, LVL = low viral load, pretreatment HCV RNA ≤400,000 IU/mL, RGT = response guided therapy, RVR = rapid virological response, HCV RNA \<50 IU/mL at treatment week 4, SD RBV = standard dose ribavirin, 1000-1200 mg/day.](medi-94-e1837-g001){#F1}

Laboratory Testing
------------------

HBsAg, HBeAg, and anti-HBe were tested using commercially available enzyme-linked immunosorbent assay kits (Abbott Laboratories, North Chicago, IL). Anti-HCV was determined by a third-generation enzyme immunoassay (Abbott Laboratories, North Chicago, IL). HCV RNA was measured using a qualitative polymerase chain reaction assay (CobasAmplicor Hepatitis C Virus Test, version 2.0; Roche Diagnostics, Branchburg, NJ; detection limit: 50 IU/mL). Serum levels of HCV RNA were quantified by the branched DNA assay (Versant HCV RNA3.0, Bayer, Tarrytown, NJ; quantification limit: 615 IU/mL) if qualitative HCV RNA seropositivity. HCV genotypes were determined using the method described by Okamoto et al.^[@R19]^ Serum HBV DNA levels were determined using the CobasAmpliPrep/CobasTaqMan HBV assay (CAP/CTM version 2.0, Roche Diagnostics, Indianapolis, IN; dynamic range 20 IU/mL--1.7 × 10^8^IU/mL).

Treatment Responses
-------------------

The primary endpoint was HCV SVR, defined as HCV RNA negativity 24 weeks after the end-of-treatment. On-treatment HCV virological responses included RVR (defined as HCV RNA negativity at treatment week 4), early virological response (EVR, defined as HCV RNA negativity at treatment week 12), and end-of-treatment virological response (EOTVR, defined as HCV RNA negativity at treatment cessation).

The study was conducted according to the guidelines of the Declaration of Helsinki and the principles of Good Clinical Practice and was approved by the local ethics committees. Written informed consent was obtained from all patients.

Statistics
----------

The primary efficacy was analyzed using the intent-to-treat (ITT) analysis. Patients who received at least 1 dose of the study medication would be included into the ITT analysis. Per-protocol (PP) analysis was also performed in population who had received 80-80-80 adherence and with HCV RNA available 24 weeks after EOT. Safety analysis included any patient who had received at least 1 dose of study medication. According to the publications from Taiwan^[@R11],[@R12],[@R18]^ and an estimated 3:2 ratio of enrolled patients with genotype 1 and genotype 2/3, we assumed a difference of SVR rate of 13% between GGT and RGT groups. Using the assumption, a sample size of 95patients per group will provide a statistical power of at least 80% to detect a between group difference at the significant level of 0.05. A withdrawal rate of 5% will be allowed and the sample size will be finally set at 100 patients per group.

Continuous variables were expressed as the mean ± standard deviation or the median (25th, 75th percentile). The Student\'s *t*-test and Mann--Whitney *U* test were used to compare continuous variables and the Chi-square and Fisher exact tests were used to compare categorical variables. Binary logistic regression analysis was used to identify the independent factors associated with SVR. All tests were 2-sided and *P* \< 0.05 was considered statistically significant. All analyses were performed using the SPSS ver17.0 statistical package (SPSS, Inc., Chicago, IL).

RESULTS
=======

Demographics and Comparison of Baseline Characteristics
-------------------------------------------------------

A total of 203 patients were enrolled into the study, 102 in GGT group and 101 in RGT group. Of GGT group, 62 patients were HCV-1 and 40 were HCV-2/3. Of RGT group, 63 patients were HCV-1 and 38 were HCV-2/3 (Fig. [2](#F2){ref-type="fig"}). Table [1](#T1){ref-type="table"} showed the demographics of all the patients and the comparison of baseline characteristics between GGT and RGT groups. The baseline characteristics were comparable between the 2 groups.

![Patient flowchart. F/U = follow-up, GGT = genotype guided therapy, GT = genotype, HBsAg = hepatitis B surface antigen, HCC = hepatocellular carcinoma, HCV = hepatitis C virus, RGT = response guided therapy, SAE = serious adverse event,.](medi-94-e1837-g002){#F2}

###### 

Demographics and Comparison of Baseline Characteristics Between Genotype-Guided and Response-Guided Group
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HCV Response
------------

The HCV treatment response was shown in Table [2](#T2){ref-type="table"}. In the ITT analysis, for patients of HCV-1/HBV, 59.7%, 83.9%, 88.7%, and 69.4% of patients in the GGT group compared with 44.4%, 92.1%, 93.7%, and 63.5% of the patients in the RGT group achieved RVR, EVR, EOTVR, and SVR (*P* = 0.108, 0.180, 0.363, and 0.571), respectively. For patients of HCV-2/3/HBV, 95.0%, 97.5%, 97.5%, and 90.0% of patients in the GGT group compared with 84.2%, 97.4%, 94.7%, and 81.6% of patients in the RGT group achieved RVR, EVR, EOTVR, and SVR (*P* = 0.149, 1.000, 0.610, and 0.342), respectively. Taken together, 77.5% of patients in the GGT group compared with 70.3% of patients in the RGT group achieved HCV SVR in the ITT analysis (*P* = 0.267), respectively.

###### 

Comparison of HCV Response Between Genotype-Guided and Response-Guided Groups
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A total of 12 patients, who did not receive 80-80-80 adherence or without HCV RNA available 24 weeks after EOT, were not included into PP analysis. In the PP analysis, for patients of HCV-1/HBV, 62.7%, 88.1%, 93.2%, and 72.9% of patients in the GGT group compared with 44.6%, 96.4%, 98.2%, and 71.4% of patients in the RGT group achieved RVR, EVR, EOTVR, and SVR (*P* = 0.063, 0.164, 0.365, and 1.000), respectively. For patients of HCV-2/3/HBV, 94.9%, 100%, 100%, and 92.3% of patients in the GGT group compared with 86.5%, 97.3%, 94.6%, and 83.8% of patients in the RGT group achieved RVR, EVR, EOTVR, and SVR (*P* = 0.256, 0.487, 0.234, and 0.303), respectively. Taken together, 80.6% of patients in the GGT group compared with76.3% of patients in the RGT group achieved HCV SVR in the PP analysis (*P* = 0.487), respectively.

Factors Associated With HCV SVR
-------------------------------

The factors associated with SVR were further analyzed. In univariate analysis, pretreatment low serum glucose levels (*P* = 0.006), low HCV RNA levels (*P* = 0.002), and RVR (*P* \< 0.001) were factors associated with HCV SVR in HCV-1/HBV dually infected patients. The multivariate analysis showed that only pretreatment low serum glucose levels (OR: 0.97, 95%CI: 0.944--0.989, *P* = 0.003) and RVR (OR: 6.05, 95%CI: 2.148 -- 17.025, *P* = 0.001) were independently associated factors (Table [3](#T3){ref-type="table"}). For HCV-2/3/HBV dually infected patients, the univariate analysis identified RVR (*P* = 0.012) as the only factor associated with HCV SVR. Further multivariate analysis demonstrated that RVR (OR: 10.68, 95%CI: 1.948--58.514, *P* = 0.006) was the only independent factors associated with HCV SVR (Table [3](#T3){ref-type="table"}). We further analyzed factors associated with HCV SVR in GGT and RGT groups, independently (Table [4](#T4){ref-type="table"}). For HCV/HBV dually infected patients in GGT group, the multivariate analysis showed that RVR (OR: 18.92, 95%CI: 4.689--76.354, *P* \< 0.001) was the only factor associated with HCV SVR. By contrast, for those in RGT group, multivariate analysis demonstrated that pretreatment HCV RNA level (OR: 0.49, 95%CI: 0.256--0.934, *P* = 0.030) was the only factor independently associated with HCV SVR.

###### 

Univariate and Multiple Logistic Regression Analyses of Factors Associated With HCV SVR in HCV-1, and HCV-2/3/HBV Dually Infected Patients
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###### 

Univariate and Multiple Logistic Regression Analyses of Factors Associated With HCV SVR of HCV/HBV Dually Infected Patients in GGT and RGT Groups
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HBV Response
------------

A total of 139 patients with baseline HBV DNA available demonstrated that HBV DNA was detectable among 45 (32.4%) patients (mean, 3.9 log~10~ IU/mL, range 1.8--7.9 log~10~ IU/mL), with no difference between the 2 groups (Table [5](#T5){ref-type="table"}). At the end-of-treatment, the HBV DNA was detectable among 13 (18.6%) patients in GGT group (mean, 3.3 log~10~ IU/mL, range 2.1--6.0 log~10~ IU/mL) and 15 (21.7%) patients in RGT group (mean, 3.4 log~10~ IU/mL, range 1.8--7.9 log~10~ IU/mL, *P* = 0.772). At 24 weeks posttreatment, the HBV DNA was detectable among 28 (40.0%) patients in GGT group (mean, 3.7 log~10~ IU/mL, range 2.2--7.1 log~10~ IU/mL) and 16 (23.2%) patients in RGT group (mean, 3.5 log~10~ IU/mL, range 2.1--7.9 log~10~ IU/mL, *P* = 0.678). Among 94 patients with undetectable HBV DNA at baseline, reappearance of HBV DNA was found in 7 (7.4%) of the 94 patients at the end-of-treatment and in 18 (19.1%) at 24 weeks posttreatment. Significantly higher rate of HBV DNA reappearance at 24 weeks posttreatment was observed in the GGT group than in the RGT group (32.6% vs 6.2%, *P* = 0.001). Six (33.3%) of the 18 patients with HBV DNA reappearance at 24 weeks posttreatment had reappeared HBV DNA level greater than 2000 IU/mL and all of them were in the GGT group. Among 45 patients with baseline detectable HBV DNA, 24 (53.3%) and 20 (44.4%) had HBV DNA undetectable in 24 at the end-of-treatment and in 24 weeks posttreatment, respectively. The rate of HBV DNA undetectable 24 weeks posttreatment did not differ between GGT (45.8%) and RGT (38.1%) groups. Among 45 patients with baseline detectable HBV DNA, none had increased HBV DNA level greater than 1 log~10~ IU/mL at the end-of-treatment and 2 had increased HBV DNA level greater than 1 log~10~ IU/mL 24 weeks posttreatment.

###### 

HBV Virological Response After PEGylated Interferon and Ribavirin Therapy
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HBsAg loss was observed in 17 (9.2%) of the 185 patients who had HBsAg data available 1 year posttreatment, including 9 (9.5%) of the 95 patients in GGT group and 8 (8.9%) of the 90 patients in RGT group (*P* = 1.000).

Safety Profile
--------------

The type of adverse events (AEs) in dual-infected patients were similar to those seen in HCV-monoinfected patients. There was no difference of incidence of AEs, serious adverse events (SAE), and dose modification between GGT and RGT groups (Table [6](#T6){ref-type="table"}). A total of 13 patients, 5 in GGT and 8 in RGT groups happened SAE during study period. Seven of the 13 patients with SAE, 4 in GGT and 3 in RGT groups, discontinued Peg-IFN/RBV therapy.

###### 

Rates of Serious Adverse Events, Grade 3 or 4 Adverse Events, Dose Modification, and Adverse Events
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Notably, there were 3 patients experienced severe acute hepatitis flare (alanine aminotransferase level \>10-folds ULN and total bilirubin level \>2-folds ULN) correlated to HBV DNA surge within 48 weeks posttreatment. One patient suffered from liver decompensation related to HBV cirrhosis. All of the 4 patients received NUC therapy immediately and were well controlled thereafter. Another patient had severe liver decompensation which was not related to HBV (HBV DNA level less than 60 IU/mL) at 4th week of Peg-IFN/RBV therapy and died within 1 month.

DISCUSSION
==========

The current study demonstrated that the concept of RGT for HCV-monoinfected patients might also be applied in HBeAg-negative HBV/HCV dually infected patients with an HCV SVR rate of 63.5% in HCV-1/HBV and 81.6% in HCV-2/3/HBV dually infected patients.

In HCV monoinfected patients, a fixed duration therapy with Peg-IFN/RBV achieved approximately 50% SVR in HCV-1 and 83% SVR in HCV-2/3 patients in Western countries.^[@R16],[@R17],[@R20]--[@R24]^ For Asian patients with HCV monoinfection, better SVR rates of approximately 77% in HCV-1 and over 90% in HCV-2/3 patients have been observed.^[@R18],[@R25]^ Different patterns of on-treatment virological responses have been reported.^[@R26]^ A shortened duration of 24-week Peg-IFN/RBV therapy could achieve a comparable SVR rate with standard 48-week therapy for HCV-1 patients with pretreatment LVL and RVR.^[@R11]--[@R14]^ Similarly, 16 weeks of Peg-IFN combined with standard dose of RBV had a noninferior SVR rate compared with 24-week therapy for HCV-2/3 patients with RVR in meta-analysis.^[@R14]^ Therefore, Peg-IFN/RBV RGT for HCV monoinfection was recommended in European and Asian-Pacific guidelines in the era before directly acting antiviral agents (DAAs) were available.^[@R6],[@R27]^

For HBV/HCV dually infected patients with active hepatitis C, the treatment duration and efficacy of Peg-IFN/RBV therapy has recently confirmed.^[@R8],[@R27],[@R28]^ A Taiwanese multicenter clinical trial demonstrated that 48 and 24 weeks of Peg-IFN/RBV therapy achieved similar HCV SVR rate between HCV/HBV dually infected and HCV-monoinfected patients, for HCV-1 or HCV-2/3 infections, respectively.^[@R8]^ The following study also revealed a durable HCV SVR in 97% of patients during long-term follow-up.^[@R10]^ Similar results were also reported from Europe and Korea.^[@R29],[@R30]^ However, these results were based on an HCV GGT with fixed duration of Peg-IFN/RBV, 48 weeks in HCV-1 and 24 weeks in HCV-2/3 patients. Whether a tailored abbreviated treatment regimen using the concept of RGT for patients with RVR could be applied for HBV/HCV dually infected patients has never been studied.

The current study first demonstrated that a tailored duration of Peg-IFN/RBV therapy according to pretreatment viral load (VL) and RVR had comparable HCV SVR rates compared with fixed duration of GGT in HBV/HCV dually infected patients with either HCV-1 or HCV-2/3 infections. These findings indicated that the strategies of RGT for HCV monoinfection could also be translated to HBV/HCV dual infections.

We also observed that pretreatment low glucose levels and RVR were factors associated with SVR in dually infected patients with HCV-1/HBV dually infections, and RVR was the only factor associated with SVR in patients with HCV-2/3 infections. These findings echoed the impact of insulin resistance on the treatment response to Peg-IFN/RBV for HCV-1-monoinfected patients^[@R31]^ and the leading role of RVR in determining the SVR to Peg-IFN/RBV therapy for HCV-monoinfected patients.^[@R32]^

Interactions between HBV and HCV are important issues in dually infected patients. HBsAg loss and DNA suppression following Peg-IFN/RBV have been observed. By contrast, reappearance of HBV DNA might occur in patients with pretreatment undetectable HBV DNA.^[@R8]^ In the current study, the rate of HBsAg loss was similar between GGT and RGT groups, both were comparable with previous reports.^[@R10],[@R33]^ The rate (19.1%) of posttreatment HBV reappearance in patients with baseline undetectable HBV DNA and the rate (44.4%) of HBV virologic response in patients with baseline detectable HBV DNA were also consistent with previous studies. Interestingly, we found that among patients with baseline undetectable HBV DNA, GGT group had a significantly higher rate of posttreatment HBV DNA reappearance than the RGT group did. The findings implicated that close observation of certain HBV/HCV dually infected patients after Peg-IFN/RBV therapy is warranted. Fortunately, only 4 patients experienced significant HBV-related clinical reactivation. All the patients were controlled after immediately treated with HBV nucleot(s)ide analogs.

Consistent with previous studies, Peg-IFN/RBV combination therapy was well tolerated with high adherence and low discontinuation rate in the current study. The incidence and severity of AEs and laboratory abnormalities were similar to those reported previously in HCV-monoinfected patients.^[@R34]^ There was also no significant difference of AEs and laboratory abnormalities between patients of GGT and RGT groups.

The substantial lower SVR rate was observed in HCV-2/3/HBV dually infected patients treated with RGT in the current study. As for HCV-2/3-monoinfected patients, an abbreviated treatment duration of Peg-IFN/RBV is not recommended for those with unfavorable predictors, such as obesity, cirrhosis, and high baseline VL, even they achieving an RVR. Nevertheless, our findings indicated that 24 and 16 weeks of Peg-IFN/RBV may be considered for low VL HCV-1/HBV and HCV-2/HBV dually infected patients, respectively, if they achieve an HCV RVR.

Recently, introduction of newly developed DAAs with or without IFN and/or RBV have a great achievement in treatment efficacy and safety for anti-HCV therapy with SVR rates of higher than 90% for HCV-1 or 2 patients.^[@R35]--[@R37]^ However, there is no DAAs data available for HCV/HBV dually infected patients. Whether the high efficacy and good safety of newly introduced DAA-based therapy for HCV monoinfection could be translated to HCV/HBV dually infected patients still needs further studies. Moreover, lack of Peg-IFN effect on HBV, the safety of DAA IFN-free regimens for HCV/HBV dually infected patients, remains to be explored carefully, in terms of HBV reactivation after HCV eradication. Peg-IFN/RBV would be the mainstay for the treatment of HBV/HCV dually infected patients before new therapeutic agents with better efficacy and safety available.^[@R38]^ Our data support a cost-effective strategy with Peg-IFN/RBV for the treatment of HBeAg-negative HCV/HBV dually infected patients and the chance to treat both infections at once, which may not be achieved by the new DAAs. Furthermore, in the era of new DAAs, our findings may also provide evidence to obviate unnecessary protease inhibitor^[@R39]^ or to conduct RGT based on HCV genotype and pretreatment/on-treatment viral kinetics when applying DAA plus Peg-IFN/RBV combination therapy for HBeAg-negative chronic dual HCV/HBV infections.^[@R40]^

In conclusion, RGT with Peg-IFN plus RBV according to HCV genotype, baseline HCV VL and RVR had comparable efficacy as GGT for HBeAg-negative HBV/HCV dually infected patients. Strategy of RGT with abbreviated regimens may be considered for the clinical settings.
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